Regulation of Rab activation at the Golgi complex
高尔基复合体 Rab 激活的调节
基本信息
- 批准号:9197321
- 负责人:
- 金额:$ 29.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AutophagocytosisBindingBiochemicalBiological AssayCarrier ProteinsCell SurvivalCellsCellular MembraneCellular biologyComplexConflict (Psychology)DataDefectDissectionEukaryotic CellGenesGoalsGolgi ApparatusGuanine Nucleotide Exchange FactorsGuanosine Triphosphate PhosphohydrolasesHealthHuman BiologyLogicMembraneMembrane Protein TrafficModelingMolecularMutateMutationOrganellesPathway interactionsPhysiologicalPlayPositioning AttributeProtein SortingsProteinsRecruitment ActivityRegulationResearchRoleSaccharomycetalesSiteSorting - Cell MovementStructureSubstrate SpecificitySumTransport VesiclesUncertaintyVesicleVesicle Transport PathwayYeast Model Systembonehuman diseasein vitro Assayin vivoparticleprotein transportpublic health relevancerab GTP-Binding Proteinsreconstitutiontraffickingyeast genetics
项目摘要
DESCRIPTION (provided by applicant): The Golgi complex is the central sorting station for nearly a third of all proteins in eukaryotic cells, but how cells regulate the flow of material through this organelle remains unknown. Protein and membrane traffic into and out of the Golgi is controlled by Rab GTPases that function by recruiting effectors to generate, transport, and tether transport vesicles. The master regulators of these essential Rab pathways are the Rab-GEF proteins that must "decide" whether to activate their substrate Rabs. The TRAPP complexes are GEFs that activate Rabs at the Golgi, but it is unknown how the timing and magnitude of TRAPP complex activity is regulated. In the budding yeast model, there are two essential Rabs that control Golgi traffic: Ypt1 (Rab1), and Ypt31/32 (Rab11). The TRAPPI complex is the established activator of Ypt1 at early Golgi compartments. The GEF for Ypt31/32 is unknown, and is the subject of controversy. The TRAPPII complex has been proposed to serve as the GEF for Ypt31/32, although firm evidence for this hypothesis is lacking. The uncertainty surrounding the GEF for this critical trafficking pathway is hindering progress in the field. Using a biochemical approach, we have now obtained data that will resolve this controversy. By purifying the TRAPPII complex and performing physiological Rab activation assays, we have discovered that TRAPPII functions as a bone fide GEF for both Ypt1 and Ypt31/32. Importantly, robust GEF activity for Ypt31/32 is strictly dependent upon the presence of membranes, thus explaining why it was not observed previously by other groups, and implying the existence of an autoinhibitory mechanism. Our long-term goal is to uncover mechanisms governing the regulation of Golgi function. The goal of this project is to determine the mechanisms regulating the activation of Ypt1 and Ypt31/32 by the TRAPP complexes. In order to achieve our research goals, we propose the following three aims: 1) Dissect the mechanistic basis for TRAPPII activation of two different Rab GTPases. In vitro assays will be used to investigate how TRAPPII can activate two different substrates, and to ask why membranes are required for activation of Ypt31/32 but not Ypt1. We will then use yeast genetics and cell biology to characterize the functional consequences of perturbing TRAPPII activity in vivo, in order to understand how the TRAPPII complex is regulated in the context of Golgi trafficking. 2) Determine the mechanism and functional significance of TRAPPIII function at the Golgi. Emerging evidence points to TRAPPIII as the physiological GEF for Ypt1 at the early Golgi. We will investigate how TRAPPIII GEF activity is regulated and what role it plays in the cell. 3) Characterize the dynamics of TRAPPII and TRAPIII association with the Golgi. We will determine whether known interacting partners directly regulate the activity and dynamics of TRAPP complexes. We will also determine whether the TRAPP complexes are regulated by crosstalk with other Golgi-localized GTPases. In sum, these studies will lead to a comprehensive model for the regulation of the essential Golgi Rab trafficking pathways.
描述(由适用提供):高尔基复合物是真核细胞中几乎所有蛋白质中几乎三分之一的中心分类站,但是细胞如何调节材料通过该细胞器的流动仍然未知。蛋白质和膜流入高尔基体受到Rab GTPases的控制,这些Rab GTPase通过招募生效者来生成,运输和绳索运输蔬菜。这些基本RAB途径的主要调节剂是Rab-GEF蛋白,必须“决定”是否激活其底物Rabs。 Trapp复合物是激活高尔基体Rabs的GEF,但未知如何调节Trapp复合活动的时间和幅度。在萌芽的酵母模型中,有两个控制高尔基体流量的必需RAB:YPT1(RAB1)和YPT31/32(RAB11)。 Trappi复合物是早期高尔基体室内YPT1的已建立活化剂。 YPT31/32的GEF尚不清楚,并且是争议的主题。尽管缺乏牢固的证据,但已提出Trappii综合体作为YPT31/32的GEF。 GEF围绕这一关键贩运途径的不确定性正在阻碍该领域的进步。使用生化方法,我们现在获得了可以解决这一争议的数据。通过纯化Trappii复合物并进行物理RAB激活评估,我们发现Trappii在YPT1和YPT31和YPT31/32方面均充当骨骼GEF。重要的是,YPT31/32的鲁棒GEF活性严格取决于机制的存在,从而解释了为什么其他群体先前未观察到它,并暗示存在自抑制机制。我们的长期目标是发现管理高尔基功能调节的机制。该项目的目的是确定TRAPP复合物对YPT1和YPT31/32的机理调节。为了实现我们的研究目标,我们提出以下三个目的:1)剖析两种不同RAB GTPase的trappii激活机械基础。体外测定将用于研究Trappii如何激活两个不同的底物,并询问为什么激活YPT31/32而不是YPT1需要机制。然后,我们将使用酵母遗传学和细胞生物学来表征体内Trappii活性的功能后果,以了解如何在高尔基运输的背景下调节Trappii复合物。 2)确定trappiii功能在高尔基体上的机制和功能意义。新兴的证据指出TrappIII是YPT1的物理GEF,我们将研究如何调节Trappiii GEF活性以及它在细胞中的作用。 3)表征Trappii和Trapiii与高尔基体关联的动力学。我们将确定已知的相互作用伙伴是否直接调节TRAPP复合物的活性和动力学。我们还将确定trapp复合物是否通过与其他高尔基体定位的GTPases串扰调节。总而言之,这些研究将导致一个综合模型,以调节基本的高尔基rab贩运途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
J Christopher Fromme其他文献
J Christopher Fromme的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('J Christopher Fromme', 18)}}的其他基金
GTPase Regulation of the Golgi Complex (Diversity Supplement 2023)
高尔基复合体的 GTPase 调节(多样性补充资料 2023)
- 批准号:
10800329 - 财政年份:2020
- 资助金额:
$ 29.02万 - 项目类别:
Regulation of Rab activation at the Golgi complex
高尔基复合体 Rab 激活的调节
- 批准号:
9005350 - 财政年份:2016
- 资助金额:
$ 29.02万 - 项目类别:
Regulation of Arf GTPase activation at the trans-Golgi network
跨高尔基体网络 Arf GTPase 激活的调节
- 批准号:
8245998 - 财政年份:2012
- 资助金额:
$ 29.02万 - 项目类别:
Regulation of Arf GTPase activation at the Golgi complex
高尔基复合体 Arf GTP 酶激活的调节
- 批准号:
9234934 - 财政年份:2012
- 资助金额:
$ 29.02万 - 项目类别:
Regulation of Arf GTPase activation at the Golgi complex
高尔基复合体 Arf GTP 酶激活的调节
- 批准号:
9415454 - 财政年份:2012
- 资助金额:
$ 29.02万 - 项目类别:
Regulation of Arf GTPase activation at the trans-Golgi network
跨高尔基体网络 Arf GTPase 激活的调节
- 批准号:
8413049 - 财政年份:2012
- 资助金额:
$ 29.02万 - 项目类别:
Regulation of Arf GTPase activation at the trans-Golgi network
跨高尔基体网络 Arf GTPase 激活的调节
- 批准号:
9000156 - 财政年份:2012
- 资助金额:
$ 29.02万 - 项目类别:
相似国自然基金
拟南芥中EIN2蛋白调控mRNA翻译并激活乙烯信号的生化机制研究
- 批准号:31870254
- 批准年份:2018
- 资助金额:60.0 万元
- 项目类别:面上项目
大米蛋白/阿魏酸的结合机制对复合物的抗氧化及模拟胃肠消化性能的调控研究
- 批准号:31760433
- 批准年份:2017
- 资助金额:38.0 万元
- 项目类别:地区科学基金项目
拟南芥fimbrin5调控花粉管生长的细胞学基础和生化机制分析
- 批准号:31671390
- 批准年份:2016
- 资助金额:60.0 万元
- 项目类别:面上项目
拟南芥微丝解聚因子第三亚家族成员生理生化功能研究
- 批准号:31670180
- 批准年份:2016
- 资助金额:65.0 万元
- 项目类别:面上项目
结合神经分类的分子超光谱成像生化指标定量分析研究
- 批准号:61240006
- 批准年份:2012
- 资助金额:10.0 万元
- 项目类别:专项基金项目
相似海外基金
Rational optimization of combinatorial therapies for the treatment of rare cystic fibrosis variants
合理优化治疗罕见囊性纤维化变异的组合疗法
- 批准号:
10736732 - 财政年份:2023
- 资助金额:
$ 29.02万 - 项目类别:
Hsp40 and Hsp70 in Membrane Protein Triage
膜蛋白分类中的 Hsp40 和 Hsp70
- 批准号:
10718226 - 财政年份:2023
- 资助金额:
$ 29.02万 - 项目类别:
Mechanisms of Neurodegeneration in CMT4B3: a Complex Pediatric Neurodevelopmental Disorder
CMT4B3 神经退行性变的机制:一种复杂的小儿神经发育障碍
- 批准号:
10750509 - 财政年份:2023
- 资助金额:
$ 29.02万 - 项目类别:
Mechanism of Substrate Unfolding by the AAA+ ATPase p97 and Binding Partners
AAA ATPase p97 和结合伙伴的底物解折叠机制
- 批准号:
10678124 - 财政年份:2023
- 资助金额:
$ 29.02万 - 项目类别:
Mechanistic Understanding of Hypoxia-Induced Peroxisome loss: Implications for Heart Failure
缺氧引起的过氧化物酶体损失的机制理解:对心力衰竭的影响
- 批准号:
10840053 - 财政年份:2023
- 资助金额:
$ 29.02万 - 项目类别: